Clinvet acquired a stake in RTI, LLC (Research Technology Innovation), a South Dakota-based Contract Research Organization (CRO) specializing in conducting preclinical trials in infectious disease research on food-producing animals. Through this acquisition, Clinvet integrates the RTI team’s preclinical expertise in immunology and infectious disease research and RTI’s research facilities in the USA, thus boosting Clinvet’s footprint and service offering in North America – notably through the addition of expertise and facilities for production animals’ studies. Moreover, RTI’s portfolio of food-producing animals’ infectious diseases research models and laboratory capabilities largely complements the range of services of Clinvet large animals’ facilities in South Africa and Morocco.

This acquisition significantly expands the scope of both organizations, bringing together well- established CROs with expertise in complementary fields and product development. Both Clinvet and RTI have served the animal health industry for more than two decades and supported the development of numerous innovative Animal Health products.

Rollie Nevins, CEO of RTI, said: “Clinvet joining Dr. Chase and I in leadership and ownership of RTI provides an assurance of the continuity service for the animal health industry as well as expanded opportunities for our great staff. Clinvet/Clinglobal becoming part of our organization allows us to increase the reach of our service and product capabilities beyond the USA. Welcoming Clinvet US also grants us to expand to new therapeutic areas like antiparasitic research. Moreover, access to proven systems and back-end resources facilitates compliance and allows us to focus on the science and clinical trial delivery.”

Dr. Chris Chase, co-founder and CSO of RTI, added: “With the joining of RTI and Clinvet, I am excited about the long term opportunities for myself and our RTI team to be a part of expanding scientific offerings to our clients and driving innovation that focuses on solutions that will benefit animals and people around the world.”

Key benefits to customers include:

• Access to a group of scientific subject matter experts spanning from parasitology, virology and pharmaceuticals to infectious diseases, immunology and vaccines;
• Clinical pathology and microbiology laboratory services, including in-vitro and in-vivo models of immunology in swine, poultry and cattle;
• A simplified approach for contracting and project lifecycle management;
• Aligned systems, processes, and data quality standards.

The exciting opportunities arising from this endeavor between Clinvet US and RTI do not end with their preclinical services. Clinglobal’s project management solutions, the comprehensive data management and statistical services from Clindata, Clinomics’ molecular biology R&D capabilities and the extensive portfolio of specialized services from Clinglobal’s strategic partners make this group an unparalleled Animal Health Product development platform. The wide-ranging solutions proposed by the group shall benefit start-ups, biotech, medium and large Animal Health companies and governmental and non-governmental funding agencies focused on alleviating the global impact of animal and human disease.